New hope for sarcoma patients: drug combo aims to shrink tumors
NCT ID NCT07547592
First seen Apr 25, 2026 · Last updated May 15, 2026 · Updated 3 times
Summary
This study tests whether adding a drug called bevacizumab (Onbevzi) to standard chemotherapy (gemcitabine and docetaxel) can shrink tumors better than chemotherapy alone in people with advanced soft tissue sarcoma. About 92 adults whose sarcoma has returned after 1-2 prior treatments will take part. The goal is to see if the combination improves response rates and delays cancer growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS OF CONNECTIVE AND SOFT TISSUE WITH AN UNSPECIFIED ANATOMICAL SITE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.